Interactions between imidazoline I-2 receptor ligands and acetaminophen in adult male rats: antinociception and schedule-controlled responding
Recent evidence suggests that imidazoline I-2 receptor ligands are suitable for combination therapy with opioids. Quantitative analysis of I-2 receptor ligands combined with non-opioid drugs is necessary for the justification of alternative pain therapies.
This study systematically examined the antihyperalgesic and response rate-suppressing effects of selective I-2 receptor ligands (2-BFI and phenyzoline) alone and in combination with acetaminophen.
Von Frey and Hargreaves tests were used to examine the antihyperalgesic effects of drugs in complete Freund's adjuvant (CFA)-induced inflammatory pain in rats. Food-reinforced schedule-controlled responding was used to assess the rate-suppressing effects of study drugs. Dose-addition and isobolographic analyses were used to assess drug-drug interactions for all assays.
2-BFI (3.2-17.8 mg/kg, i.p.), phenyzoline (17.8-100 mg/kg, i.p.), and acetaminophen (56-178 mg/kg, i.p.) all dose-dependently produced significant antinociceptive effects. When studied as combinations, 2-BFI and acetaminophen produced infra-additive to additive interactions while phenyzoline and acetaminophen produced additive to supra-additive interactions. The same drug combinations suppressed response rate in a supra-additive manner.
Quantitative analysis of the antihyperalgesic and response rate-suppressing effects suggests that I-2 receptor ligands are not well suited to combination therapy with acetaminophen.